SCHEMBL615378

SCHEMBL615378

Cc1cc(-c2cc(O)ccc2Cl)cn2nc(Nc3ccc(OCCN4CCCC4)cc3)nc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 17/20 0.68
PDGFRB P09619 6/20 0.68
YES1 P07947 6/20 0.68
ABL1 P00519 6/20 0.68
EPHB4 P54760 4/20 0.68
KDR P35968 4/20 0.68
LCK P06239 3/20 0.68
RET P07949 3/20 0.68
GAK O14976 2/20 0.68
RIPK2 O43353 2/20 0.68
BCR P11274 2/20 0.68
EPHA2 P29317 2/20 0.68
EPHB2 P29323 2/20 0.68
ABL2 P42684 2/20 0.68
EPHA4 P54764 2/20 0.68
DDR1 Q08345 2/20 0.68
CIT O14578 1/20 0.68
EPHB6 O15197 1/20 0.68
PRKD3 O94806 1/20 0.68
BRAF P15056 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612970 0.86 SRC (0.62) SRCPDGFRBYES1ABL1EPHB4
SCHEMBL615141 0.83 SRC (0.62) SRCPDGFRBYES1ABL1EPHB4
SCHEMBL231130 0.81 SRC (0.78) SRCPDGFRBYES1ABL1EPHB4
SCHEMBL41605 0.81 SRC (0.62) SRCPDGFRBYES1ABL1EPHB4
SCHEMBL4269019 0.81 SRC (1.00) SRCPDGFRBYES1ABL1EPHB4
SCHEMBL29366448 0.81 SRC (1.00) SRCPDGFRBYES1ABL1EPHB4
Hydrochloric Acid SCHEMBL4268361 0.80 SRC (0.98) SRCPDGFRBYES1ABL1EPHB4
SCHEMBL615134 0.79 SRC (0.53) SRCPDGFRBYES1ABL1EPHB4
SCHEMBL611762 0.79 SRC (0.53) SRCPDGFRBYES1ABL1EPHB4
SCHEMBL614557 0.77 SRC (0.63) SRCPDGFRBYES1ABL1EPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041195-A1 Heterocyclic compounds FOVEA PHARMACEUTICALS 2012-02-16 US claimed
US-20120041195-A1 Heterocyclic compounds FOVEA PHARMACEUTICALS 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041195-A1 Heterocyclic compounds MAP3K1, MAP3K5, MAP3K2 SRC 1204/4885PDGFRB 941/4885YES1 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.